 | Baxter and contaminated influenza vaccine
  The Baxter and contaminated influenza vaccine is in the last stages development and will be the only and primary to be based on what is known as the 'Vero cell' continuous cell line. The vaccine will not utilize any egg proteins, minimizing allergic reactions risk, the possible exposure to harmful antibiotics, and no preservatives such as thiomersal. In present day, economic technology of creating an influenza vaccine needs to maintain high quality standards of the finished product ensuring adequate amounts the Baxter and contaminated influenza vaccines are available in emergency situations.
Because influenza can be so dangerous to some people, efforts were begun soon after the identification of the influenza virus to create an effective vaccine against it. Researchers soon discovered that the many strains of flu made successful flu vaccinations considerably more difficult to achieve than in the case of other infectious diseases.
Vaccination is a technique for inducing immunity to a viral disease by artificially stimulating a person’s production of antibodies against a specific virus. Doctors inoculate the patient with a virus that has been modified to limit its ability to reproduce but is still capable of stimulating production of antibodies.
The principal flu vaccine used today, inactivated (often called “killed”) virus vaccine, is prepared by growing a human flu virus in fertilized chicken eggs, then inactivating it with formalin, a formaldehyde solution. The formalin chemically bonds to the hemaglutinin and neuraminidase spikes on the surface of each virus particle, in effect clogging them so that they can no longer infect human cells. The clogged spikes, however, still retain their power to trigger normal antibody response, thus conferring immunity to the disease.
The effectiveness of a vaccine depends on how closely the killed virus in the vaccine matches the prevailing cold virus. In tests of perfectly matched vaccines and viruses on volunteer subjects, about 70 per cent of the volunteers are made entirely immune to the flu strain. In actual practice, the effectiveness of flu vaccines varies considerably from year to year. If the wild virus matches the laboratory strain, protection approaches 70 per cent, but if the wild strain drifts, effectiveness drops dramatically.
A killed vaccine is usually administered as an annual injection. Each year people who have had previous contact with the prevailing virus strain, either from a previous year’s flu shot or from an infection caused by a similar virus, receive a single dose of vaccine—in effect, a booster for their existing store of antibodies. Those too young to have met the virus previously—the age cutoff varies according to the history of the dominant flu strain—must get two shots about a month apart to build a sufficient reservoir of antibodies. | Most Popular Common Cold And Flu ArticlesHow Does The Common Cold Affect Your Body Palpitations And Need To Cough Cough With Frothy White Sputum Types Of Rheumatic Heart Fever Pain Constant Low Grade Fever Nutritional Requirements Needed To Treat Fever Flu Symptoms With Neck And Back Pain And Muscle Aches Who Discovered Influenza Is Canada Ready For A Pandemic Influenza | |
| As both Type A and Type B flu viruses are considered a threat, most influenza vaccines are bivalent, meaning that they protect against two strains. When two variants of Type A are circulating simultaneously, a vaccine may be prepared in a trivalent form, composed of two Type A and one Type B killed viruses. Immunity begins about two weeks after injection, when the antibody level has risen sufficiently to defeat a chance encounter with flu viruses. It generally lasts at close to maximum effectiveness for about six months, but protection lessens sharply thereafter. Since the influenza season generally coincides with the coldest months of the year, most people living in temperate climates get their flu shots in autumn.
Because the immunity conferred by killed-virus vaccines is short-lived and somewhat problematical, virologists continue to search for a better type of vaccine. The most promising research is focused on attenuated, or “live,” virus vaccines, which are made with viruses that are specially bred to cause a harmless infection yet trigger flu antibodies. In the past, when such vaccines were used in Japan, China, the Soviet Union and Yugoslavia, the laboratory strains had a dangerous tendency to revert to wild viruses that caused the disease itself. But United States scientists now are experimenting with genetically stable, temperature-sensitive viruses that will grow in the relatively cool temperatures of the nose, but are unable to survive the warmer temperatures in the lungs themselves. This is common in the Baxter and contaminated influenza vaccine.
At least in theory, such a live-virus vaccine has several advantages over killed-virus vaccines. It is administered by nose drops or a nasal spray, a route that may stimulate better antibody response in the respiratory secretions, the primary line of defense against influenza. And since live-virus vaccine mimics a natural flu infection, it may give better protection against drifted strains and provide longer immunity than the current killed-virus vaccines, a Vero cell trait and evident in Baxter and contaminated influenza vaccine. | Twitter About The Common Cold Cure  | | Common Cold Tip Of The Day Laboratory experiments with volunteers given virus-laden nose drops showed that a tonsillectomy affected neither susceptibility to colds nor the severity of colds that were contracted. |
| |
